Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Novartis
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00375752
First received: September 11, 2006
Last updated: April 15, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the safety/efficacy of zoledronic acid when given by intravenous infusion every 4 weeks in addition to letrozole as endocrine therapy in postmenopausal patients with hormone responsive breast cancer
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Neoplasms |
Drug: Letrozole Drug: Zoledronic acid |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks) |
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- Tumor Response Rate (Complete Response (CR) or Partial Response (PR)) Based on MRI- or Mammography and/or Sonography According to Modified RECIST Criteria at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]Sum of longest diameter for all target lesions was reported as baseline sum LD. Baseline sum LD was used as reference to characterize objective tumor response. Response Evaluation Criteria in Solid Tumors has 4 response categories. CR (complete response) = disappearance of all target lesions, PR (partial response)= 30% decrease in sum of longest diameter of target lesions, PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions and SD(stable disease)=small changes that do not meet criteria. Analysis was underpowered due to insufficient recruitment rate.
Secondary Outcome Measures:
- Best RECIST Response Based on Central Review [ Time Frame: 6 Months ] [ Designated as safety issue: No ]Best response is defined as the best response the patients has reached during the 6 months of treatment. Response Evaluation Criteria in Solid Tumors (RECIST) has 4 response categories. CR (complete response) = disappearance of all target lesions, PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions, PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions and SD (stable disease) = small changes that do not meet criteria.
- Number of Patients With Breast-conserving Surgery [ Time Frame: Every 6 months ] [ Designated as safety issue: No ]
- Change From Baseline in Tumor Size (Longest Diameter) at Month 6 [ Time Frame: Baseline, Month 6 ] [ Designated as safety issue: No ]Tumor size (sum of longest diameter)was analyzed based on the diameters values provided with the central review.
- To Compare Pathologic Complete Response (pCR) [ Time Frame: Every 6 months ] [ Designated as safety issue: No ]
- To Compare BC Deaths and Overall Survival [ Time Frame: Every 6 months ] [ Designated as safety issue: Yes ]
- To Compare the Quality of Life Using the FACT-B Questionnaire [ Time Frame: Every 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 168 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Letrozole (LET)
Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment.
|
Drug: Letrozole
Letrozole was provided as 2.5 mg tablets for oral administration. Treatment was scheduled as 2.5 mg once daily for approximately 6.5 months.
Other Name: Femara®)
|
|
Experimental: Letrozole +Zoledronic Acid (LET+ZOL)
2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
|
Drug: Letrozole
Letrozole was provided as 2.5 mg tablets for oral administration. Treatment was scheduled as 2.5 mg once daily for approximately 6.5 months.
Other Name: Femara®)
Drug: Zoledronic acid
Zoledronic acid was provided as solution concentrate for intravenous infusion. 5 mL concentrate contained 4 mg zoledronic acid and was to be diluted for infusion in 100 mL normal saline. Treatment was scheduled as 4 mg i.v. at intervals of 4 weeks for a duration of 6 months. The duration of each infusion should not be shorter than 15 minutes.
Other Name: Zometa®
|
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Postmenopausal women with primary invasive breast cancer, histologically confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive
- Clinical Stage T1c (Size ≥ 1.5 cm), T2, T3, T4a, b, c, N0 or N1, M0 (TNM Classification). According to the modified RECIST criteria, tumors of size ≥ 1.5 cm are considered measurable by mammography and can be determined as target lesions).
- Tumor measurable by mammography, sonography and clinical examination.
- Adequate bone marrow, renal and hepatic function
- Good health status (ECOG Performance status of 0, 1 or 2)
Exclusion criteria:
- Prior treatment with letrozole or bisphosphonates. Prior and concomitant anti-breast-cancer treatments such as chemotherapy, immunotherapy / biological response modifiers (BRM's), endocrine therapy other than letrozole (including steroids), and radiotherapy. Patients who have received hormone replacement therapy (HRT) will NOT be excluded, provided that HRT is discontinued at least 2 weeks prior to entry into the study.
- Patients with unstable angina, or uncontrolled cardiac disease (e.g. Class III and IV New York Heart Association's Functional Classification, see Appendix 9) or uncontrolled endocrine disorders.
- Evidence of inflammatory breast cancer or distant metastasis.
- Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).
- History of diseases with influence on bone metabolism, such as Paget's disease, Osteogenesis Imperfecta, and primary or secondary hyperthyroidism within the 12 months prior to study entry
Other protocol-defined inclusion/exclusion criteria may apply
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375752
Locations
| Germany | |
| Novartis Investigative Site | |
| Bad Saarow, Germany | |
| Novartis Investigative Site | |
| Berlin, Germany | |
| Novartis Investigative Site | |
| Brandenburg an der Havel, Germany | |
| Novartis Investigative Site | |
| Cottbus, Germany | |
| Novartis Investigative Site | |
| Ebersberg, Germany | |
| Novartis Investigative Site | |
| Elmshorn, Germany | |
| Novartis Investigative Site | |
| Erlangen, Germany | |
| Novartis Investigative Site | |
| Essen, Germany | |
| Novartis Investigative Site | |
| Esslingen, Germany | |
| Novartis Investigative Site | |
| Essn-Ruttenscheid, Germany | |
| Novartis Investigative Site | |
| Freiburg, Germany | |
| Novartis Investigative Site | |
| Furth, Germany | |
| Novartis Investigative Site | |
| Gifhorn, Germany | |
| Novartis Investigative Site | |
| Gorlitz, Germany | |
| Novartis Investigative Site | |
| Gottingen, Germany | |
| Novartis Investigative Site | |
| Halle, Germany | |
| Novartis Investigative Site | |
| Hameln, Germany | |
| Novartis Investigative Site | |
| Hannover, Germany | |
| Novartis Investigative Site | |
| Heilbronn, Germany | |
| Novartis Investigative Site | |
| Herne, Germany | |
| Novartis Investigative Site | |
| Homburg/Saar, Germany | |
| Novartis Investigative Site | |
| Ingolstadt, Germany | |
| Novartis Investigative Site | |
| Kempten, Germany | |
| Novartis Investigative Site | |
| Koln, Germany | |
| Novartis Investigative Site | |
| Landsberg a. Lech, Germany | |
| Novartis Investigative Site | |
| Leipzig, Germany | |
| Novartis Investigative Site | |
| Lubeck, Germany | |
| Novartis Investigative Site | |
| Mainz, Germany | |
| Novartis Investigative Site | |
| Marburg, Germany | |
| Novartis Investigative Site | |
| Marktredwitz, Germany | |
| Novartis Investigative Site | |
| Maven, Germany | |
| Novartis Investigative Site | |
| Munchen, Germany | |
| Novartis Investigative Site | |
| Mutlangen, Germany | |
| Novartis Investigative Site | |
| Neunkirchen, Germany | |
| Novartis Investigative Site | |
| Offenburg, Germany | |
| Novartis Investigative Site | |
| Rheinfelden, Germany | |
| Novartis Investigative Site | |
| Rosenheim, Germany | |
| Novartis Investigative Site | |
| Saarbrucken, Germany | |
| Novartis Investigative Site | |
| Stuttgart, Germany | |
| Novartis Investigative Site | |
| Ulm, Germany | |
| Novartis Investigative Site | |
| Wiesbaden, Germany | |
| Novartis Investigative Site | |
| Wolfsburg, Germany | |
Sponsors and Collaborators
Novartis
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmeceuticals |
More Information
No publications provided
| Responsible Party: | Novartis |
| ClinicalTrials.gov Identifier: | NCT00375752 History of Changes |
| Other Study ID Numbers: | CZOL446GDE19 |
| Study First Received: | September 11, 2006 |
| Results First Received: | March 30, 2012 |
| Last Updated: | April 15, 2013 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Novartis:
|
Breast cancer Anti tumor potential Letrozole |
Zoledronic acid Neoadjuvant treatment Hormone responsive breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms Neoplasms by Site Breast Diseases Skin Diseases Letrozole Zoledronic acid Diphosphonates |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Aromatase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Bone Density Conservation Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 22, 2013